The short-form recepteur d'origine nantais (sf-RON) was found to enhance glucose metabolism in gastric cancer by activating the β-catenin/SIX1 signaling axis, which promotes tumor cell proliferation, which indicated that sf-RON might serve as a promising therapeutic target for gastric cancer [198]. This evidence concerns the gene SIX1 and neoplasm.